It is my great pleasure to welcome you to today’s second Takeda-organised ECCO 2017 satellite symposium “Targeting Disease Progression in Crohn’s Disease: Fighting an Unrelenting Enemy.”
In treating patients with Crohn’s disease, the ultimate therapeutic goal is to slow disease progression. Decisive treatment for early and long-term remission is the key to improving outcomes and potentially achieving this goal. My colleague Remo Panaccione, MD, FRCPC, will discuss the importance of introducing efficacious and well-tolerated therapy in the early stages of Crohn’s disease in the hope of catching the therapeutic window of opportunity for disease modification. Persistent inflammation is believed to lead to progressive bowel damage over time. Dr Panaccione will review how to maintain clinical remission and mucosal healing for the long term with recently proposed “treat-to-target” therapeutic strategies.
Vedolizumab is a gut-selective anti-integrin antibody that works by inhibiting leukocyte migration into gut mucosa. I will provide an overview of the latest data on the early and long-term use of vedolizumab for the treatment of patients with Crohn’s disease in both the clinical and real-world settings. These data show that early use of vedolizumab in biologic-naïve patients and those with moderate disease is associated with better clinical outcomes, and continued treatment with vedolizumab can achieve long-term remission with a favourable risk-benefit profile. The recently updated ECCO Crohn’s disease guidelines recommend consideration of vedolizumab for the treatment of patients with moderate or severe disease activity and to maintain medically-induced remission.
We believe this symposium will provide you with an ideal forum to discuss effective treatment of Crohn’s disease to make a real difference for your patients. Thank you for joining us this afternoon.
|12:40-12:45||Welcome & Introduction||CHAIR
Iris Dotan, MD
|12:45-13:00||Slowing Progression of Crohn's Disease: Decisive Treatment for Early and Long-term Remission||Remo Panaccione, MD, FRCPC|
|13:00-13:15||Early Use of Gut-Selective Therapy in Crohn's Disease for Long-term Remission||Iris Dotan, MD|
|13:15-13:20||Q&A||Iris Dotan, MD|
|Lunch will be available immediately after the symposium|
Iris Dotan, MD, is Head of the Inflammatory Bowel Disease (IBD) Center at Tel Aviv Sourasky Medical Center, a tertiary referral center for patients with IBD. Prof Dotan received her MD from the Sackler Faculty of Medicine at Tel Aviv University. Her postdoctoral fellowship was completed at the Immunobiology Center at Mount Sinai Medical Center in New York, New York, USA, and focused on intestinal epithelial cell biology. She is a specialist in internal medicine, gastroenterology, and liver diseases.
The overarching theme at the IBD Center is to provide cutting-edge care for patients and their families. Prof Dotan’s clinical and research interests focus on patient stratification as a basis for improved patient care, prevention of complications, and future cure of IBD. She has expertise in the use of biologics and novel therapies for IBD, and the follow-up of patients with ulcerative colitis before and after restorative proctocolectomy in a comprehensive, multidisciplinary pouch clinic. In addition, Prof Dotan conducts translational research in mucosal immunology focusing on the interactions of mucosal lymphocytes with their environment, specifically epithelial cell-derived mediators. She first described the new antiglycan antibodies and their relevance to Crohn’s disease a decade ago and is investigating the role of glycans in intestinal immune responses.
Remo Panaccione, MD, FRCPC, is Professor of Medicine at the Cumming School of Medicine and Director of the IBD Clinic at the University of Calgary.
Dr Panaccione received his medical degree from the University of Western Ontario in London, Ontario, Canada in 1993. He went on to complete his internal medicine and gastroenterology training at that university, and is certified as a Fellow of the Royal College of Physicians and Surgeons of Canada in internal medicine and gastroenterology. Dr Panaccione completed advanced training in IBD at the Mayo Clinic in Rochester, Minnesota, USA. He joined the University of Calgary Faculty of Medicine in 1999.
Dr Panaccione has lectured across North America on various topics in IBD and has delivered over 120 lectures in the last 5 years. He is the author of many peer-reviewed articles and book chapters on IBD. His special interest lies in the fields of advanced immunomodulation and biological therapy. Dr Panaccione is a recognized authority on the use of infliximab in Canada and co-authored the guidelines on its use for the Canadian Association of Gastroenterology. He actively participates in clinical trials of new therapeutic agents in Crohn’s disease and ulcerative colitis. Dr Panaccione is Medical Director of the Calgary chapter of Crohn’s and Colitis Canada and sits on the Medical Advisory Council of that organization.
Dr Panaccione’s other interest is medical education. He has been recognized as a Gold Star Lecturer, Small Groups Leader, and Clinical Preceptor by the Cumming School of Medicine. Dr Panaccione has been selected as Top Postgraduate Teacher in Gastroenterology by the school’s Gastroenterology Fellows three times. Most recently, he was selected as one of the university’s “Great Teachers.”